Anatara Lifesciences Gets Hong Kong Patent for Gastrointestinal Re-Programming Product; Shares Fall 8%

MT Newswires Live

May 19, 2025

Anatara Lifesciences (ASX:ANR) obtained a standard patent for its gastrointestinal re-programming product, known as GaRP, in Hong Kong, according to a Monday filing with the Australian bourse.

The patent is valid for 20 years from Oct. 9, 2020, and follows a similar grant from the European Union in September 2024, and in Australia on Jan. 28 of this year.

Anatara Lifesciences recently concluded its trial for GaRP as treatment for debilitating symptoms of digestive disorders, including irritable bowel syndrome (IBS), per the filing.

Anatara Lifesciences' shares fell 8% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2536526117"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536526117\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536526117?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-19 11:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536526117","market":"us","top_or_hot":-1,"title":"Anatara Lifesciences Gets Hong Kong Patent for Gastrointestinal Re-Programming Product; Shares Fall 8%","media":"MT Newswires Live","content":"<html><body><p> Anatara Lifesciences (ASX:ANR) obtained a standard patent for its gastrointestinal re-programming product, known as GaRP, in Hong Kong, according to a Monday filing with the Australian bourse.</p><p>The patent is valid for 20 years from Oct. 9, 2020, and follows a similar grant from the European Union in September 2024, and in Australia on Jan. 28 of this year.</p><p>Anatara Lifesciences recently concluded its trial for GaRP as treatment for debilitating symptoms of digestive disorders, including irritable bowel syndrome (IBS), per the filing.</p><p>Anatara Lifesciences' shares fell 8% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Anatara Lifesciences Gets Hong Kong Patent for Gastrointestinal Re-Programming Product; Shares Fall 8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnatara Lifesciences Gets Hong Kong Patent for Gastrointestinal Re-Programming Product; Shares Fall 8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-19 11:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Anatara Lifesciences (ASX:ANR) obtained a standard patent for its gastrointestinal re-programming product, known as GaRP, in Hong Kong, according to a Monday filing with the Australian bourse.</p><p>The patent is valid for 20 years from Oct. 9, 2020, and follows a similar grant from the European Union in September 2024, and in Australia on Jan. 28 of this year.</p><p>Anatara Lifesciences recently concluded its trial for GaRP as treatment for debilitating symptoms of digestive disorders, including irritable bowel syndrome (IBS), per the filing.</p><p>Anatara Lifesciences' shares fell 8% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANR.AU","symbol_name":"ANATARA LIFESCIENCES LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2536526117","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536526117","pubTimestamp":1747624527,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Anatara Lifesciences  obtained a standard patent for its gastrointestinal re-programming product, known as GaRP, in Hong Kong, according to a Monday filing with the Australian bourse.The patent is valid for 20 years from Oct. 9, 2020, and follows a similar grant from the European Union in September 2024, and in Australia on Jan. 28 of this year.Anatara Lifesciences recently concluded its trial for GaRP as treatment for debilitating symptoms of digestive disorders, including irritable bowel syndrome , per the filing.Anatara Lifesciences' shares fell 8% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANR.AU":"ANATARA LIFESCIENCES LTD","XAO.AU":"标普/澳交所 普通股指数","BK7067":"生物科技","BK7508":"医药生物股","XJO.AU":"标普/澳交所 200指数","XKO.AU":"标普/澳交所 300指数"},"translate_title":"Anatara Lifesciences获得胃肠道重编程产品香港专利；股价下跌8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XKO.AU":0.9,"XAO.AU":0.9,"ANR.AU":0.9,"XJO.AU":0.9},"content_text":"Anatara Lifesciences (ASX:ANR) obtained a standard patent for its gastrointestinal re-programming product, known as GaRP, in Hong Kong, according to a Monday filing with the Australian bourse.The patent is valid for 20 years from Oct. 9, 2020, and follows a similar grant from the European Union in September 2024, and in Australia on Jan. 28 of this year.Anatara Lifesciences recently concluded its trial for GaRP as treatment for debilitating symptoms of digestive disorders, including irritable bowel syndrome (IBS), per the filing.Anatara Lifesciences' shares fell 8% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}